ACH-126443 Achillion/Yale University.
Achillion, under license from Vion, is developing the nucleoside analog ACH-126443 (beta-L-Fd4C), a reverse transcriptase (RT) inhibitor, for the potential treatment of HIV and hepatitis B virus (HBV) infection. The compound is one of a series of antiviral compounds developed by Yale University [213319]. By February 2002, it had entered phase II trials for chronic HBV infection [435422]; these were ongoing in June 2002, by which time, additional phase II clinical studies for chronic HBV infection had been planned [452185], [454316].
Patel
Jignesh
J
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri, Kansas City, 5005 Rockhill Road, Kansas City, MO 64110, USA.
Mitra
Ashim K
AK
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015658:HIV Infections / Q000188:drug therapy; D006509:Hepatitis B / Q000188:drug therapy; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*; D016047:Zalcitabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D018894:Reverse Transcriptase Inhibitors; D016047:Zalcitabine; C099405:dexelvucitabine